JAZZ - Jazz Pharmaceuticals plc

QQQ $ 589.22 $ -22.45 (-3.67 %)

DIA $ 459.79 $ -6.89 (-1.48 %)

SPY $ 655.95 $ -16.95 (-2.52 %)

TLT $ 89.18 $ 0.19 (0.21 %)

GLD $ 375.04 $ -0.14 (-0.04 %)

Previous Close

$ 176.08

Open

$ 177.78

Bid

$ 175.92 x 109

Ask

$ 176.25 x 1

Day's Range

$ 174.48 - $ 178.79

52 Week Range

$ 95.49 - $ 182.99

Volume

1,840,725

Average Volume

Market Cap

10.7B

Beta (5Y Monthly)

$ 0.62

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-07-2025	03-31-2025	10-Q
4	02-26-2025	12-31-2024	10-K
5	11-07-2024	09-30-2024	10-Q
6	08-01-2024	06-30-2024	10-Q
7	05-02-2024	03-31-2024	10-Q
8	02-28-2024	12-31-2023	10-K
9	11-08-2023	09-30-2023	10-Q
10	08-09-2023	06-30-2023	10-Q
11	05-10-2023	03-31-2023	10-Q
12	03-01-2023	12-31-2022	10-K
13	11-09-2022	09-30-2022	10-Q
14	08-03-2022	06-30-2022	10-Q
15	05-04-2022	03-31-2022	10-Q
16	03-01-2022	12-31-2021	10-K
17	11-09-2021	09-30-2021	10-Q
18	08-03-2021	06-30-2021	10-Q
19	05-04-2021	03-31-2021	10-Q
20	02-23-2021	12-31-2020	10-K
21	11-02-2020	09-30-2020	10-Q
22	08-04-2020	06-30-2020	10-Q
23	05-05-2020	03-31-2020	10-Q
24	02-25-2020	12-31-2019	10-K
25	11-05-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-07-2019	03-31-2019	10-Q
28	02-26-2019	12-31-2018	10-K
29	11-06-2018	09-30-2018	10-Q
30	08-07-2018	06-30-2018	10-Q
31	05-08-2018	03-31-2018	10-Q
32	02-27-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-08-2017	06-30-2017	10-Q
35	05-09-2017	03-31-2017	10-Q
36	02-28-2017	12-31-2016	10-K
37	11-08-2016	09-30-2016	10-Q
38	08-09-2016	06-30-2016	10-Q
39	05-10-2016	03-31-2016	10-Q
40	02-23-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Overweight on Jazz P...
11/18/2025 19:21:12

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target ...

Baird Maintains Outperform on Jazz Pharmac...
11/18/2025 15:26:03

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $1...

B of A Securities Maintains Buy on Jazz Ph...
11/18/2025 12:31:37

B of A Securities analyst Jason Gerberry maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target...

jazz-pharmaceuticals-stock-rallies-on-positive-phase-3-trial-results-for-ziihera-in-advanced-gastroesophageal-cancer

Jazz Pharmaceuticals Stock Rallies On Posi...
11/17/2025 19:54:25

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3...

Morgan Stanley Maintains Overweight on Jaz...
11/17/2025 17:37:01

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price targ...

zymeworks-jazz-pharmaceuticals-stocks-climb-on-robust-gastroesophageal-trial-outcomes-and-upcoming-regulatory-plans

Zymeworks, Jazz Pharmaceuticals Stocks Cli...
11/17/2025 17:09:52

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings...

jazz-pharmaceuticals-sigma-lithium-zymeworks-and-other-big-stocks-moving-higher-on-monday

Jazz Pharmaceuticals, Sigma Lithium, Zymew...
11/17/2025 16:39:23

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
11/17/2025 12:06:42

Zymeworks And Partners Report Statisticall...
11/17/2025 11:18:46

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab a...

Jazz Pharmaceuticals Released Topline Resu...
11/17/2025 11:11:06

Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab an...

Jazz Pharma To Highlight Both Clinical And...
11/11/2025 12:48:19

Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing ...

RBC Capital Maintains Outperform on Jazz P...
11/06/2025 16:15:44

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price targ...

Jazz Pharmaceuticals Raises FY2025 GAAP EP...
11/05/2025 21:18:15

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 GAAP EPS guidance from $(9.25)-$(7.50) to $(7.10)-$(5.20) vs $(7.76) analyst e...

Jazz Pharmaceuticals Raises FY2025 Adj EPS...
11/05/2025 21:18:04

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 Adj EPS guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 analyst estimate. Na...

Jazz Pharmaceuticals Q3 Adj. EPS $8.13 Bea...
11/05/2025 21:15:16

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $8.13 per share which beat the analyst consensus estimate of ...

Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

Insights into Jazz Pharmaceuticals's Upcom...
11/04/2025 17:01:12

JP Morgan Maintains Overweight on Jazz Pha...
10/27/2025 14:32:55

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fro...

alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz

Alkermes Strikes $2.1 Billion Avadel Deal,...
10/22/2025 19:18:55

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

Avadel Pharma Announces Global Settlement ...
10/22/2025 10:34:33

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, tod...

3 Small Cap Stocks To Play As The Bantamwe...
10/17/2025 17:47:30